Nonlinear Dynamics to Distribute GeneBio’s Phenyx Worldwide
News Jun 05, 2008
Geneva Bioinformatics (GeneBio) SA and Nonlinear Dynamics have announced a worldwide distribution agreement for GeneBio’s Phenyx and Nonlinear’s Progenesis LC-MS software, whereby Nonlinear will distribute GeneBio’s Phenyx MS identification platform.
This partnership exploits the complementary technology of Phenyx and the novel Progenesis LC-MS software for label-free quantitative analysis.
Under the terms of the agreement, Nonlinear will distribute Phenyx both as a standalone software package and alongside the Progenesis LC-MS software.
The synergy between the two products, Phenyx for MS-MS identification and Progenesis LC-MS for quantitative analysis, offers customers a comprehensive solution building on the extensive reputations of the two companies in the field of proteomics.
Developed in collaboration with the Swiss Institute of Bioinformatics (SIB), Phenyx is GeneBio’s renowned software platform for the identification and characterization of proteins and peptides from mass spectrometry data, specifically designed to meet the concurrent demands of high-throughput MS data analysis and dynamic results assessment while offering a flexible user experience and an adaptable architecture to help instil confidence in results assessment.
“This is a major step forward for Phenyx and GeneBio; we are very motivated about what this distribution deal will bring,” said Nasri Nahas, CEO of GeneBio.
“Our two companies have known and respected each other for quite some time. Nonlinear’s reputation in the bioinformatics field, their extended clientele and distribution network are all first-class; this deal allows us to bring Phenyx even closer to the MS community, especially when bundled with an innovative tool like Progenesis LC-MS. We look forward to the great upsides this new collaboration will bring to both parties and to the successful expansion of our Phenyx business,” Nahas continued.
Massachusetts General Hospital (MGH) researchers have found that extracellular RNA (exRNA) in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.READ MORE
Is there a link between differences in IQ test performance and the activity of certain genes? Researchers have shown that modifications in the structure of a specific gene have a negative impact on individual test performance. This suggests that environmentally-induced epigenetic changes to our genetic material have a greater impact on intelligence than previously thought.